Esperion Therapeutics, Inc. (ESPR)

6.82 -0.03 (-0.44%) As of 10:38AM EDT. Market open.

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 218

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Sheldon L. Koenig	Pres, CEO & Director	728.91k	N/A	1966
Dr. Joanne Micale Foody FACC, M.D.	Chief Medical Officer	471.86k	N/A	1965
Dr. Kenneth J. Fiorelli	Chief Technical Operations Officer	N/A	N/A	N/A
Mr. Benjamin Church	Head of Corp. Communications & Investor Relations	N/A	N/A	N/A
Mr. Benjamin O. Looker	Gen. Counsel & Corp. Sec.	N/A	N/A	1982
Mr. Keith F. Lenden	VP of Corp. Devel. & Strategy	N/A	N/A	1973
Ms. Betty Jean Swartz	Chief Strategy Officer	N/A	N/A	N/A
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer	N/A	N/A	1973
Ms. April Seiler	Sr. Director of Project Management	N/A	N/A	N/A
Roberta Peterson	Sr. Director of National Accounts	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate governance

Esperion Therapeutics, Inc.’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.